

Certificate of Immunization P.1

University Student Health Services

Monroe Park Campus

1300 West Broad Street, Suite 2200 Box 842022 Richmond, VA 23284-2022 PH: 804-827-8047 Fax: 804-828-1093 https://health.students.vcu.edu/ https://health.students.vcu.edu/

Health Sciences Campus 1000 E. Marshall St., Room 305 Richmond, VA 23298-0201 PH: 804-828-9220 Fax: 804-828-3181

All full-time students are required by the Code of Virginia (Section 23.1-800) to provide documentation of their immunizations by a licensed health professional. If you are unable to provide appropriate documentation, vaccines may be repeated. A registration hold for the upcoming semester will be placed if all required immunizations are not up-to-date.

Name		First		Middl	o Initial	
Last		First	Middle Initial			
Date o	of Birth:	Student V#:		Mobile #	#: ()	
VCU E	Email:	VCU Address:				
Were :	you born in the U.S.A.? Yes No	If no, country of birth:		Country	of Residence	:
lmmu	nization		Dose 1 (MM/DD/YY)	Dose 2 (MM/DD/YY)	Dose 3 (MM/DD/YY)	Dose 4 (MM/DD/YY)
		REQUIRED IMMUNIZA	TIONS			
or ††	Hepatitis B (3 dose series or TWINRI 2 dose HEPLISAV-B ™)	X (circle one) OR			X	X
+	Measles, Mumps, Rubella (MMR) After 1	st birthday and ≥ 28 days apart			X	X
††	Meningococcal Vaccine One dose requi	red after 16th birthday		X	X	X
	Polio (Required for 18 and under OR fr including Afghanistan, Nigeria, and Pa	_				
	Tdap or Td (circle one) Current dose v	vithin 10 years		X	X	X
	Tuberculosis (TB) Screening/Testing form on page 4 OR complete and su	•	•	•		screening
		OPTIONAL IMMUNIZAT	TIONS			
	Diphtheria, Pertussis, Tetanus (DPT)		# doses rec:		last dose date:	
	Hepatitis A				\times	\times
	HPV: HPV4 HPV9					X
	Meningococcal Group B (MenB does not requirement)	meet the Meningococcal Vaccine				X
	Varicella (Chicken Pox) After 1st birthda disease (Day/Month/Year) (/	y and ≥ 28 days apart OR date of /)			X	X
	COVID 19: Updated Annually			X	X	X
	Influenza: Updated Annually			\times	\times	\times
	atives [†] Attach lab result confirming sonic form available through the Web F		ver : Complet	e the waiver or	n page 3 or subr	nit the



University Student Health Services

Monroe Park Campus

1300 West Broad Street, Suite 2200 Box 842022 Richmond, VA 23284-2022 PH: 804-827-8047 Fax: 804-828-1093 https://health.students.vcu.edu/

Health Sciences Campus

1000 E. Marshall St., Room 305 Richmond, VA 23298-0201 PH: 804-828-9220 Fax: 804-828-3181 https://health.students.vcu.edu/

Nam	me: Date of Birth:	Stu	dent V#		
	Additional Vaccination Requirements Generally F	tequired by Clinical Tra	ining Sites		M/DD/YY 1 Dose 2 MM/DD/YY must be
	ease verify requirements with your clinical site. For up-to-date vaccine info it https://www.cdc.gov/vaccines/adults/rec-vac/index.html#other . Click o				
	COVID 19: Updated annually			MM/	DD/YY
	Influenza: Update annually			MM/	DD/YY
†	Varicella (Chicken Pox) Two doses after 1st birthday and ≥ 28 days apart OR scopy quantitative lab report. (Titer is not required if doses of vaccine spaced	_	f Immunity with a	Dose 1 MM/DD/YY	
†	Hepatitis B Titer Serological confirmation of immunity with copy of quantita	tive lab report			
	Alternatives† Attach lab result confirming serological immunity				
	Tuberculosis(TB)Testing Undergo two-step Tuberculin skin test (TST) OR hav	e 1 Interferon Gamma Rele	ease Assay Test (IGR	4)	
	Tests must be done at least 7 days apart but no more than 30 days be repeated. Test 1: Date Placed: Date Read Result(mm)_Test 2: Date Placed:	positi positi ositivenegative or administer Two-Step	ivenegative ivenegative *Attach copy of TST.		
—— Hea	ealthcare Provider or Health Department Signature	 		ne	



Waivers, Consent, and Exemptions

University Student Health Services

Monroe Park Campus

1300 West Broad Street, Suite 2200 Box 842022 Richmond, VA 23284-2022 PH: 804-827-8047 Fax: 804-828-1093

https://health.students.vcu.edu/

Health Sciences Campus

1000 E. Marshall St., Room 305 Richmond, VA 23298-0201 PH: 804-828-9220 Fax: 804-828-3181 https://health.students.vcu.edu/

Name:	Date of Birth	n: Student V#	
Hepatitis B Vaccine Waiver			
	nation on the risk associated with ase and I choose not to be vaccina	hepatitis B disease, availability and effectiveness of ated against hepatitis B disease.	any
Signature of Student or Parent/	Legal Guardian	Date	
Meningococcal Vaccine Waiver			
		meningococcal disease, availability and effectivenes accinated against meningococcal disease	s of any
Signature of Student or Parent/	Legal Guardian	Date	
The law requires that parental p form should be signed by the pa	rents so that medical care may b ans, and staff nurses of VCU Stud	ars and younger o provide medical or surgical care to minors. This cor be carried out promptly without unnecessary delays. I dent Health Services to examine, interview, test and, i	l hereby
Signature of Student or Parent/	Legal Guardian	Date	
Medical Exemption			
	nia § 22.1-271.2, C (ii), I certify that alth. The vaccine(s) is (are) specif	at administration of the vaccine(s) designated below v fically contraindicated because	vould be
• • •		les:[]; Rubella:[]; Mumps:[]; HBV:[]; Varicella:[]; Influ porary [] and expected to preclude immunizations un	
Date (MM/DD/YY):			
Circohum of Madical During	I salah Danasatan Afficial	D-t-	
Signature of Medical Provider/H	realth Department Official	Date	

Religious Exemption

Any student who objects on the grounds that administration of immunizing agents conflicts with his or her religious tenets or practices shall be exempt from the immunization requirements unless an emergency or epidemic of disease has been declared by the Board of Health. An affidavit of religious exemption must be submitted on a Certificate of Religious Exemption (Form CRE-1) found online by visiting health.students.vcu.edu, under the Immunizations tab, and then under the Forms & Documents page.



Virginia Tuberculosis Risk Assessment

Name:__

University Student Health Services

Monroe Park Campus

Date of Birth:_____

1300 West Broad Street, Suite 2200 Box 842022 Richmond, VA 23284-2022 PH: 804-827-8047 Fax: 804-828-1093

https://health.students.vcu.edu/

Health Sciences Campus

Student V#____

1000 E. Marshall St., Room 305 Richmond, VA 23298-0201 PH: 804-828-9220 Fax: 804-828-3181 https://health.students.vcu.edu/

First screen for TB Symptoms (check all that apply):					
If present, evaluate for active TB disease. If none, complete the risk factor portion below. Have you had a prior positive TB test (PPD or IGRA)? YesNo *If yes, please complete the TB symptom survey form on page 5 and sign below. Use this tool to identify asymptomatic individuals 6 years and older for latent TB infection (LTBI) testing. • Re-testing should only be done in persons who previously tested negative and have new risk factors since the last assessment. • A negative Tuberculin Skin Test (TST) or Interferon Gamma Release Array (IGRA) does not rule out active TB disease. • Once your information is reviewed by Student Health, you may be contacted for further follow-up information. Check appropriate risk factors below. TB infection testing is recommended if any of the risks below are checked. If TB infection result is positive and active TB disease is ruled out, TB infection treatment is recommended. —Birth, travel, or residence in a country with an elevated TB rate ≥ 3 months • Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. • IGRA is preferred over TST for non-US-born persons ≥ 2 years old. • Clinicians may make individual decisions based on the information supplied during the evaluation. Individuals who have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be considered for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal failure or on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned	st screen for TB Symptoms (check all that apply):				
Have you had a prior positive TB test (PPD or IGRA)? YesNo *If yes, please complete the TB symptom survey form on page 5 and sign below. Use this tool to identify asymptomatic individuals 6 years and older for latent TB infection (LTBI) testing. • Re-testing should only be done in persons who previously tested negative and have new risk factors since the last assessment. • A negative Tuberculin Skin Test (TST) or Interferon Gamma Release Array (IGRA) does not rule out active TB disease. • Once your information is reviewed by Student Health, you may be contacted for further follow-up information. Check appropriate risk factors below. TB infection testing is recommended if any of the risks below are checked. If TB infection result is positive and active TB disease is ruled out, TB infection treatment is recommended. —	NoneCough (3 weeks or more)HemoptysisFeverWeight LossPoor AppetiteNight SweatsFatigue				
#If yes, please complete the TB symptom survey form on page 5 and sign below. Use this tool to identify asymptomatic individuals 6 years and older for latent TB infection (LTBI) testing. Re-testing should only be done in persons who previously tested negative and have new risk factors since the last assessment. A negative Tuberculin Skin Test (TST) or Interferon Gamma Release Array (IGRA) does not rule out active TB disease. Once your information is reviewed by Student Health, you may be contacted for further follow-up information. Check appropriate risk factors below. TB infection testing is recommended if any of the risks below are checked. If TB infection result is positive and active TB disease is ruled out, TB infection treatment is recommended. Birth, travel, or residence in a country with an elevated TB rate ≥ 3 months Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individuals who have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be considered for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal failure or on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer.	present, evaluate for active TB disease. If none, complete the risk factor portion below.				
Use this tool to identify asymptomatic individuals 6 years and older for latent TB infection (LTBI) testing. Re-testing should only be done in persons who previously tested negative and have new risk factors since the last assessment. A negative Tuberculin Skin Test (TST) or Interferon Gamma Release Array (IGRA) does not rule out active TB disease. Once your information is reviewed by Student Health, you may be contacted for further follow-up information. Check appropriate risk factors below. TB infection testing is recommended if any of the risks below are checked. If TB infection result is positive and active TB disease is ruled out, TB infection treatment is recommended.					
Use this tool to identify asymptomatic individuals 6 years and older for latent TB infection (LTBI) testing. Re-testing should only be done in persons who previously tested negative and have new risk factors since the last assessment. A negative Tuberculin Skin Test (TST) or Interferon Gamma Release Array (IGRA) does not rule out active TB disease. Once your information is reviewed by Student Health, you may be contacted for further follow-up information. Check appropriate risk factors below. TB infection testing is recommended if any of the risks below are checked. If TB infection result is positive and active TB disease is ruled out, TB infection treatment is recommended. Birth, travel, or residence in a country with an elevated TB rate ≥ 3 months Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individuals who have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be considered for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal failure or on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned					
 Re-testing should only be done in persons who previously tested negative and have new risk factors since the last assessment. A negative Tuberculin Skin Test (TST) or Interferon Gamma Release Array (IGRA) does not rule out active TB disease. Once your information is reviewed by Student Health, you may be contacted for further follow-up information. Check appropriate risk factors below. TB infection testing is recommended if any of the risks below are checked. If TB infection result is positive and active TB disease is ruled out, TB infection treatment is recommended. Birth, travel, or residence in a country with an elevated TB rate ≥ 3 months Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individuals who have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be considered for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal failure or on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned 	if yes, please complete the 1D symptom survey form on page 3 and sign below.				
assessment. A negative Tuberculin Skin Test (TST) or Interferon Gamma Release Array (IGRA) does not rule out active TB disease. Once your information is reviewed by Student Health, you may be contacted for further follow-up information. Check appropriate risk factors below. TB infection testing is recommended if any of the risks below are checked. If TB infection result is positive and active TB disease is ruled out, TB infection treatment is recommended. Birth, travel, or residence in a country with an elevated TB rate ≥ 3 months Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individuals who have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be considered for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal failure or on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned	Use this tool to identify asymptomatic individuals 6 years and older for latent TB infection (LTBI) testing.				
 A negative Tuberculin Skin Test (TST) or Interferon Gamma Release Array (IGRA) does not rule out active TB disease. Once your information is reviewed by Student Health, you may be contacted for further follow-up information. Check appropriate risk factors below. TB infection testing is recommended if any of the risks below are checked. If TB infection result is positive and active TB disease is ruled out, TB infection treatment is recommended. Birth, travel, or residence in a country with an elevated TB rate ≥ 3 months Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individuals who have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be considered for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal failure or on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned 					
TB infection testing is recommended if any of the risks below are checked. If TB infection result is positive and active TB disease is ruled out, TB infection treatment is recommended. Birth, travel, or residence in a country with an elevated TB rate ≥ 3 months Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individuals who have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be considered for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal failure or on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned	• A negative Tuberculin Skin Test (TST) or Interferon Gamma Release Array (IGRA) does not rule out active TB disease.				
If TB infection result is positive and active TB disease is ruled out, TB infection treatment is recommended.	Check appropriate risk factors below.				
 Birth, travel, or residence in a country with an elevated TB rate ≥ 3 months Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individuals who have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be considered for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal failure or on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned 	TB infection testing is recommended if any of the risks below are checked.				
 Birth, travel, or residence in a country with an elevated TB rate ≥ 3 months Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individuals who have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be considered for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal failure or on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned 	If TB infection result is positive and active TB disease is ruled out, TB infection treatment is recommended.				
 Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individuals who have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be considered for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal failure or on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned 	Birth toward annual days in a country side or almost dTB or to 2 months				
 European countries. ■ IGRA is preferred over TST for non-US-born persons ≥ 2 years old. ■ Clinicians may make individual decisions based on the information supplied during the evaluation. Individuals who have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be considered for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal failure or on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned 	KITTO TRAVEL OF RECIDENCE IN A COLINTRY WITH AN ELEVATED LIK PATE > 4 MONTOS				
 ■ IGRA is preferred over TST for non-US-born persons ≥ 2 years old. ■ Clinicians may make individual decisions based on the information supplied during the evaluation. Individuals who have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be considered for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal failure or on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned 	birth, travet, or residence in a country with all elevated 15 rate 2 3 months				
Clinicians may make individual decisions based on the information supplied during the evaluation. Individuals who have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be considered for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal failure or on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned	 Includes countries other than the United States (US) , Canada, Australia, New Zealand, or Western and North 				
for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal failure or on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned	 Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. 				
Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal failure or on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned	 Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. 				
Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal failure or on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned	 Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individuals who have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be considered 				
or on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned	 Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individuals who have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be considered 				
Immunosuppression, current or planned	 Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individuals who have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be considered for further screening based on the risk estimated during the evaluation. 				
	 Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individuals who have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be considered for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease 				
HIV infection, injection drug use, organ transplant recipient, treatment with TNF-alpha antagonist (e.g., infliximab, etanercept, others),	 Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individuals who have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be considered for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal failure 				
	 Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individuals who have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be considered for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal failure or on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. 				
steroids (equivalent of prednisone \geq 15 mg/day for \geq month) or other immunosuppressive medication	 Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individuals who have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be considered for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal failure or on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned HIV infection, injection drug use, organ transplant recipient, treatment with TNF-alpha antagonist (e.g., infliximab, etanercept, others). 				
Close contact to someone with infectious TB disease at any time	 Includes countries other than the United States (US), Canada, Australia, New Zealand, or Western and North European countries. IGRA is preferred over TST for non-US-born persons ≥ 2 years old. Clinicians may make individual decisions based on the information supplied during the evaluation. Individuals who have traveled to TB-endemic countries for the purpose of medical or health tourism < 3 months may be considered for further screening based on the risk estimated during the evaluation. Medical conditions increasing risk for progression to TB disease Radiographic evidence of prior healed TB, low body weight (10% below ideal), silicosis, diabetes mellitus, chronic renal failure or on hemodialysis, gastrectomy, jejunoileal bypass, solid organ transplant, head and neck cancer. Immunosuppression, current or planned HIV infection, injection drug use, organ transplant recipient, treatment with TNF-alpha antagonist (e.g., infliximab, etanercept, others). 				

Provider Signature (if indicated)

Signature of Student or Parent/Legal Guardian

None, no TB testing indicated at this time.

Date

Date

Once your form is reviewed, you may be contacted for more information if indicated.



Tuberculosis Symptom Survey

University Student Health Services

Monroe Park Campus

1300 West Broad Street, Suite 2200 Box 842022 Richmond, VA 23284-2022

PH: 804-827-8047 Fax: 804-828-1093 https://health.students.vcu.edu/

Health Sciences Campus

1000 E. Marshall St., Room 305 Richmond, VA 23298-0201 PH: 804-828-9220 Fax: 804-828-3181 https://health.students.vcu.edu/

Name:	Dat	e of Birth:	Student V#
Complete IF history of POSITIVE *Positive TB Test Date:			GRA (T-Spot or QFT)**OR Positive IGRA Date
*Enclose copy of positive TB test do			se copy of report; IGRA + Quantiferon Gold or T-Spot
Last Chest X-Ray Date:	Result:		Enclose copy of latest chest x-ray report
Have you taken medication for a TB			
			Date Completed:
INHRifar			HP (12 week DOT)3HR
Are you interested in discussing late	n+ TR infection	on troatment w	ith a clinician? Ves No
Do you currently have any of the following t			
Cough lasting more than three weeks?	Yes	No No	, or 1.5,.
Unexplained weight loss?	Yes	No	
Loss of appetite?	Yes	No	
Unexplained fatigue?	Yes	No	
Fever and/or night sweats?	Yes	No	
Blood tinged sputum production?	Yes	No	
If "Yes" to any questions, please exp	I lain further, i	I ncluding date (of onset and any treatment
I am aware that the six symptoms list should promptly report to my health			s/symptoms of active tuberculosis disease that I
Signature of Student			Date
For Healthcare Provider Use: I have reviewed the above informat LTBI treatment discussed:	_		ent's information as indicated above.
Healthcare Provider Signature		Date	Phone